These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38597154)

  • 1. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07).
    de Wild SR; van Roozendaal LM; de Wilt JHW; van Dalen T; van der Hage JA; van Duijnhoven FH; Simons JM; Schipper RJ; de Munck L; van Kuijk SMJ; Boersma LJ; Linn SC; Lobbes MBI; Poortmans PMP; Tjan-Heijnen VCG; van de Vijver KKBT; de Vries J; Westenberg AH; Strobbe LJA; Smidt ML
    Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38597154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).
    van Roozendaal LM; de Wilt JH; van Dalen T; van der Hage JA; Strobbe LJ; Boersma LJ; Linn SC; Lobbes MB; Poortmans PM; Tjan-Heijnen VC; Van de Vijver KK; de Vries J; Westenberg AH; Kessels AG; Smidt ML
    BMC Cancer; 2015 Sep; 15():610. PubMed ID: 26335105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment.
    Tinterri C; Canavese G; Gatzemeier W; Barbieri E; Bottini A; Sagona A; Caraceni G; Testori A; Di Maria Grimaldi S; Dani C; Boni L; Bruzzi P; Fernandes B; Scorsetti M; Zambelli A; Gentile D;
    Br J Surg; 2023 Aug; 110(9):1143-1152. PubMed ID: 37471574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial.
    Andersson Y; Bergkvist L; Frisell J; de Boniface J
    Br J Surg; 2021 Sep; 108(9):1105-1111. PubMed ID: 34010418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
    Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
    Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Optimal treatment of the axilla after positive sentinel lymph node biopsy in early invasive breast cancer. Early results of the OTOASOR trial].
    Sávolt A; Musonda P; Mátrai Z; Polgár C; Rényi-Vámos F; Rubovszky G; Kovács E; Sinkovics I; Udvarhelyi N; Török K; Kásler M; Péley G
    Orv Hetil; 2013 Dec; 154(49):1934-42. PubMed ID: 24292111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends on Axillary Surgery in Nondistant Metastatic Breast Cancer Patients Treated Between 2011 and 2015: A Dutch Population-based Study in the ACOSOG-Z0011 and AMAROS Era.
    Poodt IGM; Spronk PER; Vugts G; van Dalen T; Peeters MTFDV; Rots ML; Kuijer A; Nieuwenhuijzen GAP; Schipper RJ
    Ann Surg; 2018 Dec; 268(6):1084-1090. PubMed ID: 28742702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of completion axillary dissection for patients with cT1-2N0 breast cancer undergoing total mastectomy with positive sentinel lymph nodes.
    Schwieger L; Postlewait LM; Subhedar PD; Geng F; Liu Y; Gillespie T; Arciero CA
    J Surg Oncol; 2024 Mar; 129(3):468-480. PubMed ID: 37955191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De-escalation of axillary surgery in patients outside Z0011 criteria.
    Giannakou A; Gooch J; Gergelis KR; Weiss A
    Surgery; 2023 Aug; 174(2):416-418. PubMed ID: 37156648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.
    de Boniface J; Filtenborg Tvedskov T; Rydén L; Szulkin R; Reimer T; Kühn T; Kontos M; Gentilini OD; Olofsson Bagge R; Sund M; Lundstedt D; Appelgren M; Ahlgren J; Norenstedt S; Celebioglu F; Sackey H; Scheel Andersen I; Hoyer U; Nyman PF; Vikhe Patil E; Wieslander E; Dahl Nissen H; Alkner S; Andersson Y; Offersen BV; Bergkvist L; Frisell J; Christiansen P; ;
    N Engl J Med; 2024 Apr; 390(13):1163-1175. PubMed ID: 38598571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary management for young women with breast cancer varies between patients electing breast-conservation therapy or mastectomy.
    Tadros AB; Moo TA; Stempel M; Zabor EC; Khan AJ; Morrow M
    Breast Cancer Res Treat; 2020 Feb; 180(1):197-205. PubMed ID: 31938938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
    Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
    Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
    Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncological Safety of Skipping Axillary Lymph Node Dissection in Patients with Clinical N0, Sentinel Node-Positive Breast Cancer Undergoing Total Mastectomy.
    Chun JW; Kang E; Kim HK; Lee HB; Moon HG; Lee JW; Han W
    Ann Surg Oncol; 2024 May; 31(5):3168-3176. PubMed ID: 38368292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic accuracy of sentinel lymph node biopsy in determining the axillary lymph node metastasis.
    Okur O; Sagiroglu J; Kir G; Bulut N; Alimoglu O
    J Cancer Res Ther; 2020; 16(6):1265-1268. PubMed ID: 33342782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of non-sentinel lymph node metastasis in breast cancer with 1-2 sentinel lymph node macrometastases underwent total mastectomy: a case-control study.
    Huang Z; Wu Z; Zou QQ; Xie YJ; Li LH; Huang YP; Wu FM; Huang D; Pan YH; Yang JR
    World J Surg Oncol; 2023 Apr; 21(1):125. PubMed ID: 37024930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extracapsular extension in the positive sentinel lymph node: a marker of poor prognosis in cT1-2N0 breast cancer patients?
    Vane MLG; Willemsen MA; van Roozendaal LM; van Kuijk SMJ; Kooreman LFS; Siesling S; de Wilt HHW; Smidt ML
    Breast Cancer Res Treat; 2019 Apr; 174(3):711-718. PubMed ID: 30610488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.